News

TB R&D Weekly Update: Podcast Interview with Peter Andersen

[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″]

Listen to Peter Andersen Podcast


Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure” that we covered in a previous TB R&D Weekly Update. The article is published in Nature Medicine in February 2011. In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development.

Additional TB R&D News:

New findings on drug tolerance in TB suggest ideas for shorter cures

BC Scientists Pioneer Method to Trace TB Outbreak

Traditional drug-discovery model ripe for reform

Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis

A multistage tuberculosis vaccine that confers efficient protection before and after exposure

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...